読み込み中
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
前日終値
$73.16
+$0.945 · +1.31%
日中の時刻はETです。市場データは遅延する場合があります。
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
日中レンジ
現在 $73.16
52週レンジ
現在 $73.16
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
82
大幅な割安
センチメント
52
まちまち
リスク
51
やや高いリスク
モメンタム
40
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
日中レンジ
現在 $73.16
52週レンジ
現在 $73.16
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 4.51億 USD | 1.83億 USD | 1744.7万 USD | 2581.6万 USD | 5702.7万 USD |
| 売上原価 | 3068.4万 USD | 1282.6万 USD | 159.3万 USD | 95.5万 USD | 207.5万 USD |
| 粗利益 | 4.21億 USD | 1.7億 USD | 1585.4万 USD | 2486.1万 USD | 5495.2万 USD |
| 研究開発 | 6432.2万 USD | 5338.6万 USD | 5031.2万 USD | 4262.4万 USD | 4171.2万 USD |
| 販売・一般管理 | 4.27億 USD | 2.37億 USD | 1.09億 USD | 4494.9万 USD | 2539.7万 USD |
| 営業費用 | 4.92億 USD | 2.91億 USD | 1.59億 USD | 8757.3万 USD | 6710.9万 USD |
| 受取利息 | 1574.7万 USD | 1501.4万 USD | 1033.7万 USD | 349.9万 USD | 3.6万 USD |
| 支払利息 | 893.5万 USD | 744.7万 USD | 322.5万 USD | 206.4万 USD | — |
| 減価償却費と償却費 | 181.6万 USD | 122.5万 USD | 87.7万 USD | 32.6万 USD | 31.2万 USD |
| 営業利益 | −7096.9万 USD | −1.21億 USD | −1.43億 USD | −6271.2万 USD | −1215.7万 USD |
| 純利益 | −6641.8万 USD | −1.16億 USD | −1.36億 USD | −6209.1万 USD | −1382.7万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$103
上昇余地（40.79%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI9647.38万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM7960.51万0.10%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF3419.15万0.04%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO2791.69万0.20%139.17億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB2309.43万0.22%108.2億 USD0.44%$206.49+3.00%
Invesco Pharmaceuticals ETFPJP1806.47万3.29%5.48億 USD0.58%$122.88+1.56%
Vanguard Russell 2000 ETFVTWO1787.3万0.10%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA1475.85万0.07%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBInvesco Pharmaceuticals ETFPJPVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
